CD28 and ICOS are key immune modulators that play roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways as demonstrated in multiple preclinical disease models.

Under the agreement, Alpine will receive an upfront payment of $60 million and will be eligible to receive development, regulatory, and commercial milestone payments of up to $805 million. Alpine will also be eligible for tiered royalties on net sales of ALPN-101. AbbVie will have the option to exclusively license ALPN-101.

Alpine will conduct a phase II clinical study in systemic lupus erythematosus. AbbVie will conduct all future clinical development, manufacturing, and commercialization for ALPN-101.

Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...

AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...

AbbVie, Jacobio to collaborate on SHP2 inhibitors
AbbVie and Jacobio Pharmaceuticals announced they are partnering to develop and market SHP2 inhibitors, which target a node in cancer and immune cells.